Current Report Filing (8-k)
August 28 2017 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 28,
2017
Creative Medical Technology Holdings, Inc.
(Exact name of registrant as specified in its
charter)
Nevada
|
|
000-53500
|
|
87-0622284
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
2017 W Peoria Avenue, Phoenix, AZ 85029
|
(Address of principal executive offices)
|
Registrant’s telephone number, including
area code:
(602) 680-7439
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company
x
Emerging growth company If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
On August 28, 2017, Creative Medical Technology
Holdings, Inc. (the “
Company
”) issued a press release announcing the completion of enrollment in the Company’s
clinical trial assessing safety and efficacy of its Caverstem
TM
procedure to treat erectile dysfunction in patients
who do not respond to currently available treatments.
The press release, furnished as Exhibit 99.1
to this Form 8-K, may contain forward-looking statements. Such forward-looking statements are based on information presently available
to the Company’s management and are current only as of the date made. Actual results could also differ materially from those
anticipated as a result of a number of factors, including, but not limited to, those discussed in the Company’s Annual Report
on Form 10-K for the year ended December 31, 2016, and subsequent reports filed by the Company with the Securities and Exchange
Commission (the “
Commission
”). For those reasons, undue reliance should not be placed on any forward-looking
statement. The Company assumes no duty or obligation to update or revise any forward-looking statement, although it may do so from
time to time as management believes is warranted or as may be required by applicable securities law. Any such updates or revisions
may be made by the registrant by filing reports with the Commission, through the issuance of press releases or by other methods
of public disclosure.
|
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits.
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release dated August 28, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Creative Medical Technology Holdings, Inc.
|
|
|
Date: August 28, 2017
|
By:
|
/s/ Timothy Warbington
|
|
|
Timothy Warbington, Chief Executive Officer
|